| Autor: |
L W, Moreland, L W, Heck, W J, Koopman, P A, Saway, T C, Adamson, Z, Fronek, R D, O'Connor, E E, Morgan, J P, Diveley, S P, Richieri, D J, Carlo, S W, Brostoff |
| Rok vydání: |
1996 |
| Předmět: |
|
| Zdroj: |
The Journal of rheumatology. 23(8) |
| ISSN: |
0315-162X |
| Popis: |
To determine whether modulation of activated T cells occurs in patients with rheumatoid arthritis (RA) after immunization with T cell receptor (TCR) V beta 17 peptides, a phase I trial was initiated to investigate the safety and feasibility of TCR peptide immunization as a therapeutic approach in RA.15 patients with moderate to severe RA were given an intramuscular injection of one of 4 doses (10, 30, 100, and 300 micrograms) of the V beta 17 peptide vaccination, followed by a booster injection of the same dose of vaccine 3 weeks later. Patients were followed for 48 weeks.The product was well tolerated and no serious adverse events attributable to the vaccine were observed. This was an uncontrolled phase I trial, however; decreases in patients joint scores were observed at all followup visits starting at 4 weeks after primary immunization. Activated V beta 17 T cells (IL-2R+) in peripheral blood were decreased (or = 20%) in 3/5 patients in the 100 micrograms group after initial measurement at Week 2 and 3/4 patients in the 300 micrograms group 3 weeks after immunization. Lymphocyte proliferation in response to the V beta 17 peptide was detected at 6 weeks or later after primary inoculation in 6/15 patients (40%) immunized.Further controlled studies are required to assess the biologic and clinical efficacy of this treatment approach. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
